MedTrace Logo

Anti-inflammatory Therapy Following Selective Laser Trabeculoplasty

NCT00485108 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2015-09-23

No results posted yet for this study

Summary

The type of anti-inflammatory medication used post selective laser trabeculoplasty (SLT) may have an impact on the intra-ocular pressure (IOP) lowering effect of SLT. This study will evaluate the IOP lowering effect of SLT following the topical administration of one of the following: prednisolone 1%, ketorolac 0.5% or artificial tears.

Conditions

  • Primary Open Angle Glaucoma
  • Pseudoexfoliation Glaucoma

Interventions

DRUG

prednisolone 1%

eye drop once in each eye treated, 4 times / day for 5 days post-laser

DRUG

ketorolac 0.5%

eye drop once in each eye treated, 4 times / day for 5 days post-laser

DRUG

Artificial Tears (Methyl cellulose drops)

eye drop once in each eye treated, 4 times / day for 5 days post-laser

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Glaucoma Research Society of Canada

    collaborator OTHER

  • Queen's University

    lead OTHER

Principal Investigators

  • Rob J Campbell, MD, MSc · Queen's University

  • Delan Jinapriya, MD · Queen's University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2009-06-30
Completion
2014-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00485108 on ClinicalTrials.gov